Ozempic May Fight Addiction Too — Massive Study of 600,000 Veterans Finds Shocking Results

Everyone knows Ozempic helps people lose weight. But a landmark study involving more than 600,000 US veterans has uncovered something nobody expected — the drug may also be one of the most powerful addiction-fighting treatments ever discovered.

The Study

Researchers at Washington University School of Medicine in St Louis analysed medical records from 606,434 US veterans — all of whom had type 2 diabetes and were taking either a GLP-1 drug like Ozempic, Wegovy, Mounjaro or Zepbound, or an older class of diabetes medication.

The findings, published in The BMJ — one of the world's most prestigious medical journals — were striking. People taking GLP-1 drugs were approximately 14% to 20% less likely to develop substance use disorders involving alcohol, nicotine, cannabis, cocaine, or opioids compared to those on older diabetes medications.

For those already struggling with addiction, the benefits were even more dramatic. People with existing substance use disorders who were taking GLP-1 drugs experienced fewer overdoses, fewer drug-related hospitalisations, fewer emergency department visits, and fewer drug-related deaths.

Why Ozempic Might Fight Addiction

The science behind this discovery is fascinating — and it starts with understanding how GLP-1 drugs actually work in the brain.

Most people know GLP-1 drugs as gut hormones that signal the brain to feel full. But GLP-1 is not just produced in the gut. It is also active in the brain itself, where the receptors it binds to cluster in regions governing reward, motivation and stress — the same brain circuitry that gets hijacked by addiction.

When someone becomes addicted to alcohol, opioids, cocaine or nicotine, their brain's reward system is rewired to prioritise the addictive substance above almost everything else. The craving is not a lack of willpower — it is a biological compulsion driven by dysregulated reward circuits.

GLP-1 drugs appear to calm these reward circuits. Patients taking Ozempic and similar medications have repeatedly reported, often spontaneously, that they had lost interest in alcohol, cigarettes, and other substances they previously craved. Scientists initially dismissed these reports as anecdotal. This study suggests they were onto something real.

A Surprise That Has No Precedent

What makes this finding truly remarkable is the breadth of substances affected. Previous addiction treatments — like naltrexone for alcohol or methadone for opioids — work on one substance at a time, targeting specific receptors. Nothing in medicine has ever shown the ability to reduce craving and addiction across multiple completely different substances simultaneously.

"This pattern of people losing their cravings across a broad range of addictive substances has no precedent in medicine," wrote the lead researchers. "GLP-1 drugs are the first type of medication to show potential benefit across multiple substance types simultaneously."

The study found reduced risks across cannabis, alcohol, cocaine, nicotine, opioids — substances that have completely different chemical mechanisms and target completely different receptors in the brain. The only common thread is the reward system — and that is exactly where GLP-1 drugs appear to act.

What It Means for the Addiction Crisis

The implications of this discovery are enormous. The United States is in the grip of a devastating opioid crisis, an alcohol use disorder epidemic, and a nicotine addiction problem that costs the healthcare system hundreds of billions of dollars annually.

Current addiction treatments are effective but vastly underused. Medications like naltrexone, buprenorphine and methadone are prescribed by addiction specialists — a small and overworked population of clinicians. Patients who need these treatments often cannot access them.

GLP-1 drugs already exist in the opposite situation. They are prescribed at enormous scale by primary care doctors across the country. The delivery system to reach millions of patients already exists. If GLP-1 drugs can be formally approved for addiction treatment, they could reach patients who would never make it to an addiction specialist.

Important Caveats

Researchers and addiction medicine specialists are urging caution about getting ahead of the science.

Dr Anna Lembke, a Stanford University addiction medicine specialist, noted that while some clinicians are already prescribing GLP-1s off-label for addiction, the drugs do not work the same way for everyone and carry risks — including gastrointestinal side effects, pancreatitis, and kidney conditions — that must be weighed carefully.

The study is observational — it found an association between GLP-1 use and lower addiction rates, but it cannot definitively prove that the drugs caused the reduction. Multiple randomised controlled trials are now underway, including one at the National Institute on Drug Abuse evaluating semaglutide specifically for alcohol reduction, that should provide more definitive answers in the coming years.

Key Takeaways

• A study of 606,434 US veterans published in The BMJ found GLP-1 drugs reduce addiction risk by 14-20% across all major substances
• Substances affected include alcohol, nicotine, cannabis, cocaine, and opioids simultaneously — unprecedented in medicine
• People with existing addictions on GLP-1 drugs had fewer overdoses, hospitalisations and drug-related deaths
• GLP-1 drugs appear to work by calming the brain's reward circuits — the same system hijacked by addiction
• This is the first medication class ever to show benefit across multiple completely different addictive substances
• Randomised controlled trials are now underway to confirm the findings
• Experts urge caution — the study shows association not causation, and GLP-1 drugs carry their own risks
• Published in The BMJ by Washington University School of Medicine researchers